SER-109
Phase 3Completed 0 watching 0 views this week📈 Rising
69
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Clostridioides Difficile Infection
Conditions
Clostridioides Difficile Infection
Trial Timeline
Oct 23, 2017 → Apr 29, 2022
NCT ID
NCT03183141About SER-109
SER-109 is a phase 3 stage product being developed by Seres Therapeutics for Clostridioides Difficile Infection. The current trial status is completed. This product is registered under clinical trial identifier NCT03183141. Target conditions include Clostridioides Difficile Infection.
Hype Score Breakdown
Clinical
27
Activity
18
Company
2
Novelty
9
Community
10
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02437500 | Pre-clinical | Completed |
| NCT03183141 | Phase 3 | Completed |
Competing Products
7 competing products in Clostridioides Difficile Infection
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| AZD5148 | AstraZeneca | Phase 2 | 52 |
| AZD5148 + Placebo | AstraZeneca | Phase 1 | 33 |
| C.difficile vaccine | Pfizer | Phase 3 | 76 |
| Ridinilazole + Vancomycin | Summit Therapeutics | Phase 3 | 74 |
| Ridinilazole + Vancomycin | Summit Therapeutics | Phase 3 | 74 |
| REC-3964 | Recursion Pharmaceuticals | Phase 2 | 47 |
| SER-109 | Seres Therapeutics | Pre-clinical | 15 |